格隆汇2月10日丨复星医药(02196.HK)公告，上海复星医药(集团)股份有限公司(以下简称“公司”)控股子公司桂林南药股份有限公司就注射用硫酸多黏菌素B(以下简称“药品1”)、上海朝晖药业有限公司就盐酸拉贝洛尔注射液(以下简称“药品2”)的药品注册上市申请已分别获国家药品监督管理局受理。药品1、药品2均为化学药品。药品1拟用于对常规疗法耐药、对本品敏感的革兰氏阴性菌感染(如铜绿假单胞菌感染等)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.